Zura Bio (NASDAQ:ZURA) Issues Quarterly Earnings Results

Zura Bio (NASDAQ:ZURA) posted its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02), Zacks reports.

Zura Bio Trading Down 4.6%

ZURA traded down $0.22 during midday trading on Thursday, hitting $4.42. The company’s stock had a trading volume of 302,954 shares, compared to its average volume of 846,377. Zura Bio has a 52-week low of $0.97 and a 52-week high of $4.68. The firm has a 50-day moving average price of $3.22 and a two-hundred day moving average price of $2.03. The firm has a market cap of $287.06 million, a P/E ratio of -6.31 and a beta of 0.24.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZURA. Chardan Capital reissued a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. HC Wainwright decreased their price objective on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 19th. Wall Street Zen raised shares of Zura Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Oppenheimer reduced their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Bank of America Corp DE grew its position in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the first quarter valued at $72,000. Jane Street Group LLC purchased a new position in shares of Zura Bio in the second quarter valued at $113,000. Finally, JPMorgan Chase & Co. grew its holdings in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,052,732 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.